56-Year-Old Woman with T2DM and Obesity on a GLP-1 RA, SGLT2 Inhibitor, and Metformin is organized by Pri-Med.
Release Date: 06/12/2023
Expiration Date: 06/12/2024
Description:
Join us for a case-based presentation focused on advancing incretin-based pharmacotherapy in individuals with both type 2 diabetes mellitus (T2DM) and obesity who are falling short of their treatment goals. Through engaging discussions, we will delve into proven strategies to optimize the use of incretin-based therapies. We will also guide you on how to effectively reassess treatment goals for patients on new regimens, empowering you to adapt and personalize therapies to achieve better patient outcomes.
Learning Objectives:
• Discuss how to advance newer incretin-based pharmacotherapy in people with T2DM and obesity who are not meeting therapeutic goal
• Describe how to reassess if a patient’s treatment goals are being met on a new regimen